Need help? Our team of experienced experts is here for you with full support.
AKA-173
Retatrutide
Cat. No.
AKA-173
CAS No.
2381089-83-2
MF
C221H342N46O68
MW
4731.42
Retatrutide is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R).
Advanced Equipments & Extensive Production Expertise
Commercial Manufacturing
Stable Quality
Customization Supporting
Technical Data
Description
Storage and Shipping
References
Product Name
Retatrutide
CAS No.
2381089-83-2
MF
C221H342N46O68
MW
4731.42
Specification
98%
Research Area
GIPR/GLP-1R/GCGR receptor Agonist,obesity and type 2 diabetes
Description
Retatrutide is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). Packing: 10mg, 20mg, 50mg, 100mg, 500mg, 1g, 5g, 10g, 1kg Availability: Under Development (current pilot scale, production validation in 3-4 month, DMF filing in 12 month)
Documents
Certificate of Analysis (COA), API specification, Safety Data Sheet (SDS/MSDS), evidence of GMP compliance, Stability data / Stability summary, etc.
Storage and Shipping
Store in a cool & dry place, keep away from strong light and heat.
References
[1]. Tamer Coskun, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism. 2022 Sep 6;34(9):1234-1247.e9.
Disclaimer
This product is intended solely for scientific research or regulatory filing purposes. We do not provide products or services to individuals, please strictly comply with all applicable laws, regulations, and the committed use. Use for any other purpose is strictly prohibited.
Related Products
* Some statements have not been evaluated by national authorities. * Some products are not intended to diagnose, treat, cure, or prevent any disease. * For literature supporting, please contact us directly.